Designing anti-influenza aptamers: Novel quantitative structure activity relationship approach gives insights into aptamer - Virus interaction

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Musafia, Boaz ^a   Oren Banaroya, Rony ^a,c   Noiman, Silvia ^b  

^a BioVent Ltd   (Israel)

^b Pontifax Inc   (Israel)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APTAMER; BV02 APTAMER; BV11 APTAMER; BV13 APTAMER; BV14 APTAMER; BV19 APTAMER; BV19G APTAMER; BV19H APTAMER; BV24 APTAMER; BV24A APTAMER; BV24B APTAMER; BV24C APTAMER; BV24D APTAMER; BV24E APTAMER; BV35A APTAMER; BV35B APTAMER; BV35E APTAMER; BV35F APTAMER; BV35G APTAMER; BV35H APTAMER; BV35M APTAMER; BV35N APTAMER; BV35O APTAMER; BV35P APTAMER; BV35R APTAMER; BV42 APTAMER; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG MECHANISM; DRUG SCREENING; FEMALE; INFLUENZA; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; DOG; DRUG DESIGN; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MDCK CELL LINE; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIVIRAL AGENTS; APTAMERS, NUCLEOTIDE; DOGS; DRUG DESIGN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; ORTHOMYXOVIRIDAE INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901297354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097696     Document Type: Article

References (45)

1. Hurt AC, Holien JK, Barr IG (2009) In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 53: 4433-4440.
2. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363-370. (Pubitemid 46787981)
3. Preziosi P (2011) Influenza pharmacotherapy: present situation, strategies and hopes. Expert Opin Pharmacother 12: 1523-1549.
4. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024.
5. Taubenberger JK, Morens DM (2010) Influenza: the once and future pandemic. Public Health Rep 125 Suppl 3: 16-26.
6. Weinstock DM, Zuccotti G (2009) The evolution of influenza resistance and treatment. JAMA 301: 1066-1069.
7. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
8. Hayden FG (2013) Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respi Viruses 7 Suppl 1: 63-75.
9. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
10. Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, et al. (2009) Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 4: e7788.
11. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, et al. (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196: 1493-1499. (Pubitemid 351411986)
12. Jeon SH, Kayhan B, Ben-Yedidia T, Arnon R (2004) A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J Biol Chem 279: 48410-48419. (Pubitemid 39540998)
13. Bouchard PR, Hutabarat RM, Thompson KM (2010) Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50: 237-257.
14. Stoltenburg R, Reinemann C, Strehlitz B (2007) SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 24: 381-403. (Pubitemid 47391579)
15. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
16. Binning JM, Leung DW, Amarasinghe GK (2012) Aptamers in virology: recent advances and challenges. Front Microbiol 3: 29.
17. Aquino-Jarquin G, Toscano-Garibay JD (2012) RNA aptamer evolution: two decades of SELEction. Int J Mol Sci 12: 9155-9171.
18. Huynen MA (1996) Exploring phenotype space through neutral evolution. J Mol Evol 43: 165-169. (Pubitemid 26315117)
19. Bing T, Yang X, Mei H, Cao Z, Shangguan D (2010) Conservative secondary structure motif of streptavidin-binding aptamers generated by different laboratories. Bioorg Med Chem 18: 1798-1805.
20. Fischer NO, Tok JB, Tarasow TM (2008) Massively parallel interrogation of aptamer sequence, structure and function. PLoS One 3: e2720.
21. Platt M, Rowe W, Knowles J, Day PJ, Kell DB (2009) Analysis of aptamer sequence activity relationships. Integr Biol (Camb) 1: 116-122.
22. Roulet E, Busso S, Camargo AA, Simpson AJ, Mermod N, et al. (2002) High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites. Nat Biotechnol 20: 831-835. (Pubitemid 34836762)
23. Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, et al. (2011) Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther 21: 299-314.
24. Delisi C, Crothers DM (1971) Prediction of RNA secondary structure. Proc Natl Acad Sci U S A 68: 2682-2685.
25. Nussinov R, Pieczenik G, Griggs JR, Kleitman DJ (1978) Algorithms for Loop Matchings. SIAM J Appl Math 35: 68-82.
26. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
27. Mathews DH, Disney MD, Childs JL, Schroeder SJ, Zuker M, et al. (2004) Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A 101: 7287-7292. (Pubitemid 38638025)
28. Zuker M, Stiegler P (1981) Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res 9: 133-148.
29. Hofacker IL, Fontana W, Stadler PF, Bonhoeffer LS, Tacker M, et al. (1994) Fast folding and comparison of RNA secondary structures. MonatshChem 125: 167-188.
30. Sidwell RW, Smee DF (2000) In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 48: 1-16.
31. SantaLucia J, Jr. (1998) A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc Natl Acad Sci U S A 95: 1460-1465.
32. Peyret N (2000) Prediction of Nucleic Acid Hybridization: Parameters and Algorithms. Detroit, MI.: Wayne State University.
33. Golbraikh A, Shen M, Xiao Z, Xiao YD, Lee KH, et al. (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17: 241-253. (Pubitemid 37062785)
34. Kapetanovic IM (2008) Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 171: 165-176.
35. Choi SK, Lee C, Lee KS, Choe SY, Mo IP, et al. (2012) DNA aptamers against the receptor binding region of hemagglutinin prevent avian influenza viral infection. Mol Cells 32: 527-533.
36. Vaillant A, Juteau JM, Lu H, Liu S, Lackman-Smith C, et al. (2006) Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob Agents Chemother 50: 1393-1401.
37. Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, et al. (2009) Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137: 673-681.
38. Bernstein DI, Goyette N, Cardin R, Kern ER, Boivin G, et al. (2008) Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob Agents Chemother 52: 2727-2733.
39. Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, et al. (2009) Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virol J 6: 214.
40. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, et al. (1988) Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 85: 6132-6136.
41. De Clercq E (2001) 2001 ASPET Otto Krayer Award Lecture. Molecular targets for antiviral agents. J Pharmacol Exp Ther 297: 1-10.
42. Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, et al. (1997) Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol 52: 98-104. (Pubitemid 27318624)
43. Neurath AR, Strick N, Li YY (2002) Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect Dis 2: 27.
44. Gopinath SC, Misono TS, Kawasaki K, Mizuno T, Imai M, et al. (2006) An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. J Gen Virol 87: 479-487.
45. Park SY, Kim S, Yoon H, Kim KB, Kalme SS, et al. (2011) Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Ther 21: 395-402.